Share

April 2022; 12 (2) Research

Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease

Andrew McGarry, Peggy Auinger, Karl D. Kieburtz, Amy-Lee Bredlau, Steven M. Hersch, H. Diana Rosas
First published February 8, 2022, DOI: https://doi.org/10.1212/CPJ.0000000000001161
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
42

Share

Article Information

vol. 12 no. 2 131-138
DOI: 
https://doi.org/10.1212/CPJ.0000000000001161
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received October 29, 2021
  • Accepted January 31, 2022
  • First Published February 8, 2022.

Article Versions

Copyright & Usage: 
© 2022 American Academy of Neurology

Author Disclosures

    1. Andrew McGarry, MD,
    2. Peggy Auinger, MS,
    3. Karl D. Kieburtz, MD, MPH,
    4. Amy-Lee Bredlau, MD,
    5. Steven M. Hersch, MD, PhD and
    6. H. Diana Rosas, MD
  1. Andrew McGarry, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1) Clintrex (commercial entity)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Peggy Auinger, MS,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Karl D. Kieburtz, MD, MPH,
    4. Scientific Advisory Boards:

    1. Consultant: The United States National Institutes of Health (NIH, NINDS) Michael J Fox Foundation Blackfynn Neuropore Novartis Roche/Genentech Synagile

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. patent pending on software system to track adverse events associated with prescribed medications

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultant: Acceleron, Acorda, Alkahest, Amicus, Annexon, Aptinyx, Avion, Axovant, BioMarin, Biotie, Blackthorn, Centrexion, Clintrex, Concert, Cynapsus, Denali, Dr Reddy, Genzyme, Inhibikase, Intec, Ipsen, Jazz, Knopp, Kyowa Kirin, Lundbeck, Medgenesis, Monosol, Neurocrine, Neuroderm, Neuropore, Novartis, Otsuka, Pfizer, Pharma2B, Photopharmics, Prana Biotechnology, Prothena, PTC, Roche/Genentech, Sage Bionetworks, Sarepta, Serina, Sunovion, Synagile, Syneos, Takeda, Teva, UCB Pharma, Ultragenyx, Uniqure, US WorldMeds, Vaccinex, vTv Therapeutics, Voyager, Weston Brain Institute, Zambon

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Institutes of Health NINDS and NCATS

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. MJ Fox Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Amy-Lee Bredlau, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Axsome Therapeutics, Senior Medical Director 2019-present Stock/Stock Options, Medical Equipment & Materials: Axsome Therapeutics, 2019-present

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Steven M. Hersch, MD, PhD and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Huntington's disease, editorial Board 2012- uncompensated.

    Patents:

    1. 1. A High Sensitivity Immunoassay for the detection of frataxin in biofluids - work at Voyager Therapeutics to develop a biofluid marker for Friedreich's Ataxia 2. COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON’S DISEASE - contributions to developing an intraparenchymal gene therapy for Huntington's disease as part of work at Voyager Therapeutics.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I have been employed by Eisai Inc since 01/2021 as a Vice President, Clinical Development I have also been employed since 2001 by Massachusetts General Hospital/Harvard Medical School where I am currently a Professor of Neurology, part time. My work relevant to this manuscript stems from this role and being the principal investigator of the CREST-E study, which was supported by NIH. since joining Voyager.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1) FDA/ODA R01-FD003359, PI, 2006-2011 2) NIH/NCCIH, U02-AT000613, PI, 2009-2017 3) NIH NINDS 5R21NS103056, investigator, 2017-2020 4) NIH NINDS 5R01NS106384, investigator, 2018-2023

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. H. Diana Rosas, MD
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Huntington's disease

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. Neurocrine 2. Prilenia

    Research Support, Government Entities:

    1. NIH NINDS P01 NS058793 NIH, NINDS R01 NS042861 NIH, NCCAM U01 AT000613 NIH, NINDS NS106384

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. Voyager Therapeutics

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Neurology (AM), Cooper University Healthcare at Rowan University, Camden, NJ; Center for Health and Technology (PA), University of Rochester, NY; Department of Neurology (KDK), University of Rochester, NY; University of Rochester (A-LB), NY; and Department of Neurology (SMH, HDR), Harvard Medical School, Boston, MA.
  1. Correspondence
    Dr. McGarry mcgarry-andrew{at}cooperhealth.edu
View Full Text

Article usage

Article usage: March 2022 to August 2023

AbstractFullPdfSource
Feb 202222006Highwire
Mar 202213904Highwire
Apr 2022246166Highwire
May 202219175Highwire
Jun 202212922Highwire
Jul 20228125Highwire
Aug 20225842Highwire
Sep 20225624Highwire
Oct 20223911Highwire
Nov 20227932Highwire
Dec 20223900Highwire
Jan 20234311Highwire
Feb 20236000Highwire
Mar 20235401Highwire
Apr 20232712Highwire
May 20232200Highwire
Jun 20231800Highwire
Jul 20232210Highwire
Aug 20232351Highwire

Cited By...

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me